Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 106 clinical trials
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

lymphadenopathy
metastasis
abiraterone
bone disease
soft tissue disease
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Multicenter Study of Hypofractionated Postoperative Radiotherapy in Patients Diagnosed With Prostate Carcinoma

The objective of this study is to evaluate, in patients diagnosed with prostate cancer who undergo radical prostatectomy and who require postoperative radiotherapy, tolerance in terms of acute and chronic GU and GI toxicity and efficacy in terms of biochemical control and survival, as well as of quality of life, …

adjuvant
prostate carcinoma
lymphadenectomy
lymph node disease
ct scan
  • 0 views
  • 19 Feb, 2024
  • 19 locations
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

gonadotropin
luteinising hormone
gonadotrophin
adrenal
bladder cancer
  • 2 views
  • 19 Feb, 2024
  • 16 locations
Interactive Decision Aid for Men Diagnosed With Prostate Cancer

Prostate cancer is the second leading cause of cancer related deaths in the western world (National Cancer Institute, 2011). Prostate cancer diagnosis relates to significant psychological distress (Roesch et al, 2005; Hervouet et al, 2005).

cancer diagnosis
  • 0 views
  • 19 Feb, 2024
  • 1 location
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand

Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer …

prostate specific antigen
molecular imaging
pet/mri
fluciclovine (18f)
conventional imaging
  • 0 views
  • 19 Feb, 2024
  • 1 location
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression

This study will evaluate whether a lifestyle intervention focused on weight loss, EMPOWER, reduces prostate cancer progression at 12 months among men with biochemical recurrence following local treatment for prostate cancer. Half of the men will be randomized to receive the EMPOWER intervention, while the other half will receive standard …

local therapy
ct scan
definitive therapy
definitive treatment
testosterone level
  • 0 views
  • 19 Feb, 2024
  • 1 location
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

positron emission tomography
digital rectal examination
pet/ct scan
multiparametric magnetic resonance imaging
  • 0 views
  • 19 Feb, 2024
  • 1 location
Postop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer

Prostate cancer is the second most common cancer among Canadian men of which approximately 20-30% present with high-risk tumour characteristic.

adjuvant
gonadotropin releasing hormone
gonadotropin
eligard
ct scan
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

measurable disease
prostatic neoplasm
antiandrogen therapy
prostatic neoplasms, castration-resistant
combined modality therapy
  • 0 views
  • 19 Feb, 2024
  • 22 locations
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

soft tissue disease
metastatic castration-resistant prostate cancer
bone scan
progressive disease
castration-resistant prostate cancer
  • 0 views
  • 19 Feb, 2024
  • 5 locations